Interní Med. 2018; 20(1): 44-48 | DOI: 10.36290/int.2018.051

Differential diagnosis of monoclonal gammopathies from the point of clinical practice
II. Monoclonal gammopathy of undetermined significance and other monoclonal gammopathies of the „non-malignant“ origin

prof. MUDr. Vlastimil ©čudla, CSc.1,2, doc. MUDr. Mgr. Jiří Minařík, Ph.D.2, MUDr. Tomáą Pika, Ph.D.2, doc. MUDr. Jaroslav Bačovský, CSc.2
1 3. interní klinika NRE LF UP a FN v Olomouci
2 Hemato-onkologická klinika FN a LF UP v Olomouci

Monoclonal gammopathies (MG) are a very heterogeneous group of both malignant and dominantly non-malignant conditionsthat are characterized by the presence of monoclonal immunoglobulin (MIg, „paraprotein“) or its structural components in serumand/or urine. The aim of this paper is to present the spectrum of „non-malignant“ MG, their diagnostics and differential diagnosticsfrom the point of primary health care. The paper includes diagnostic criteria of selected nosologocal units, especially monoclonalgammopathy of undetermined significance (MGUS) and its subtypes, monoclonal gammopathy of renal significance (MGRS),AL-amyloidosis and light chain deposition disease (LCDD), including their position in routine clinical practice.

Keywords: monoclonal gammopathy, monoclonal gammopathy of undetermined significance, monoclonal gammopathy of
renal significance, AL amyloidosis, light chain deposition disease, differential diagnosis

Received: April 20, 2017; Accepted: April 20, 2017; Published: March 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
©čudla V, Minařík J, Pika T, Bačovský J. Differential diagnosis of monoclonal gammopathies from the point of clinical practice
II. Monoclonal gammopathy of undetermined significance and other monoclonal gammopathies of the „non-malignant“ origin. Interní Med. 2018;20(1):44-48. doi: 10.36290/int.2018.051.
Download citation

References

  1. Kyle RA, Durie BGM, Rajkumar SV, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspective risk factors for progression and guidelines for monitoring and management. Leukemia 2010; 24: 1121-1127. Go to original source... Go to PubMed...
  2. Hájek R, Adam Z, ©čudla V, et al. Diagnostika a léčba mnohočetného myelomu. Doporučení vypracované Českou myelomovou skupinou. Transf Hematol dnes 2012; 18: 6-89.
  3. Rajkumar SV, Dimopoulos MA, Blade J, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15: 538-548. Go to original source... Go to PubMed...
  4. Rajkumar SV, Kyle RA, Buadi FK. Advances in the diagnosis, classification, risk stratification and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence. Mayo Clin Proc 2010; 85: 945-948. Go to original source... Go to PubMed...
  5. Adam Z. Diferenciální diagnostika monoklonálních gamapatií. Inter Med pro praxi 2004; 5: 279-283.
  6. Van De Donk NW, Mutis T, Poddighe PJ. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Inter J Lab Hematol 2016; doi:10.1111/ijlh.12504. Go to original source... Go to PubMed...
  7. Bladé J, Rosinol L, Cibeira MT, et al. Pathogenesis and progression of monoclonal gammopathy of undetermined significance. Leukemia 2008; 22: 1651-1657. Go to original source... Go to PubMed...
  8. ©čudla V. Monoklonální gamapatie nejistého významu. Postgr Med 2006; 8: 42-49.
  9. Schmitz MF, Otten HG, Franssen LE et al. Secondary monoclonal gammopathy of undetermined significance after allogeneic stem cell transplantation in multiple myeloma. Haematologica 2014; 99: 1846-1853. Go to original source... Go to PubMed...
  10. Giraldo P, Rubio-Félix D, Delgado P, et al. Transient monoclonal gammopathies. Study of 34 cases. Sangre 1994; 39: 351-355. Go to PubMed...
  11. Karfo R, Benchekroun L, Zohoun A, et al. Difficulties in interpreting the monoclonal gammopathy of chance discovery: transitional gammopathy case in a significant inflammatory syndrome. Ann Biol Clin 2015; 73: 495-497. Go to original source... Go to PubMed...
  12. BMJ Best Practice 2016. Multiple myeloma-Differential diagnosis. z http://www.bestpractice.bmj.com/best-practice/monograph/179/diagnosis/differential.html. Získáno 23. 3. 2017.
  13. Merlini G, Wechalekar D, Palladini G. Systemic light chain amyloidosis: an update for treating physicians. Blood 2013; 121: 5124-5130. Go to original source... Go to PubMed...
  14. Ryąavá R. Systémové amyloidózy a jejich léčba. Praha: Maxdorf Jessenius/Sv61 2013: s. 124.
  15. ©čudla V, Adam Z, Hájek T, et al. Diagnostika a léčba systémové AL amyloidózy. Transf Hematol dnes 2013; 19: supl. 1: 3-52.
  16. Leung NL, Bridoux F, Hutchison CA, et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood 2012; 20: 4292-4295. Go to original source... Go to PubMed...
  17. Bridoux F, Leung N, Hutchinson CA, et al. Diagnosis of monoclonal gammopathy of renal significance. Kidney Int 2015; 87: 698-711. Go to original source... Go to PubMed...
  18. Nasr S, Valeri AM, Cornell LD, et al. Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin J Amer Soc Nephrol 2012; 7: 231-239. Go to original source... Go to PubMed...
  19. Merlini G, Palladini G. Enlightening light chain deposition disease. Blood 2015; 126: 2770-2771. Go to original source... Go to PubMed...
  20. ©čudla V, Pika T. Nemoc z ukládání lehkých řetězců imunoglobulinu (light chain deposition disease). Vnitř Lék 2012; 58: 38-43. Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.